Evolving treatment landscape: 18 years of managing melanoma in a single patient

Author:

Biosse-Duplan GaranceORCID,Murphy Suzanne,Durrani Amer,Corrie Pippa

Abstract

A 57-year-old woman diagnosed with primary melanoma was managed with a wide variety of treatments over 18 years. Given her long history of disease, the array of therapies she has received range from those no longer recommended to those recently approved. This case highlights the extraordinary rate at which both the medical and surgical melanoma treatment landscape has evolved, alongside how professional consensus has changed over the past two decades. It also demonstrates the innovation and collaboration required between the patient and the multidisciplinary team, as well as how external factors such as national guidelines, eligibility for clinical trials and drug funding in the National Health Service (NHS) alter a management plan, presenting yet another set of challenges when managing cancer patients in the modern era.

Publisher

BMJ

Subject

General Medicine

Reference22 articles.

1. Common cancer sites — cancer STAT facts. Available: https://seer.cancer.gov/statfacts/html/common.html [Accessed 20 Jul 2021].

2. Melanoma skin cancer survival statistics [Internet]. Cancer Research UK, 2015. Available: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer/survival [Accessed 15 Jan 2021].

3. Recent advances in the treatment of melanoma. Longo dl, editor;Curti;N Engl J Med,2021

4. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

5. National Institute for Health and Care Excellence . Ipilimumab for previously treated advanced unresectable or metastatic melanoma (Technology appraisal guidance [TA268]), 2012. Available: https://www.nice.org.uk/guidance/ta268

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Dabrafenib/pembrolizumab/trametinib;Reactions Weekly;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3